Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Aug;32(8):980-986.
doi: 10.1038/s41431-024-01611-0. Epub 2024 Jun 5.

POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program

Affiliations
Case Reports

POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program

Marta Baptista Freitas et al. Eur J Hum Genet. 2024 Aug.

Abstract

Protection of Telomeres Protein 1 (POT1) protein is an essential subunit of the shelterin telomere binding complex, regulating telomere length. Some POT1 gene pathogenic variants (PV) lead to telomere elongation, genomic instability and higher risk of cancer. POT1 tumour predisposition syndrome (POT1-TPD) has autosomal dominant inheritance and unknown penetrance. It is associated with increased risk of cutaneous melanoma, chronic lymphocytic leukaemia, angiosarcoma and gliomas. In this work, we aim to describe a broader cancer phenotype related to POT1-TPD, in three families (two with a four generation pedigree, one with a five generation pedigree). The three index cases were referred to our oncogenetic centre for genetic counselling due to their personal history of cancer. Two underwent clinical exome sequencing of 4,867 genes associated with Mendelian genetic diseases, and another underwent gene panel sequencing including POT1, which identified three different POT1 PV: NC_000007.14(NM_015450.2):c.349C>T; NC_000007.14(NM_015450.2):c.233T>C and NC_000007.14(NM_015450.2):c.818G>A; already described in the literature. Referenced relatives, did a target genetic test (according to the POT1 PV identified in the family). In total, 37 individuals were tested (51.4% females), median age of 46 (22-81) years, with POT1 PV detected in 22. POT1-TPD was observed, but also a higher incidence of other cancers (other sarcomas, papillary thyroid cancer, early onset prostate cancer and leukaemia). These findings contribute to an increase in our knowledge about POT1 PV, and it can play a role in the definition of future POT1 PV screening criteria, POT1 carrier surveillance protocols (possibly considering screening for all types of sarcomas) and in genetic counselling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Family A - four generation pedigree with several family members affected with different primary cancers.
Family members with a cancer diagnosis are shown as filled symbol. All tested family members are marked in the pedigree, others were not tested. + : positive for NC_000007.14(NM_015450.2):c.349C>T variant; − : negative for NC_000007.14(NM_015450.2):c.349C>T variant; (+) : obligate carrier of NC_000007.14(NM_015450.2):c.349C>T variant.
Fig. 2
Fig. 2. Family B - five generation pedigree with multiple family members affected with different primary cancers.
Family members with a cancer diagnosis are shown as filled symbol. All tested family members are marked in the pedigree, others were not tested. + : positive for NC_000007.14(NM_015450.2):c.233T>C variant; − : negative for NC_000007.14(NM_015450.2):c.233T>C variant; (+) : obligate carrier of NC_000007.14(NM_015450.2):c.233T>C variant.
Fig. 3
Fig. 3. Family C - four generation pedigree with several family members affected with different primary cancers.
Family members with a cancer diagnosis are shown as filled symbol. All tested family members are marked in the pedigree, others were not tested. + : positive for NC_000007.14(NM_015450.2):c.818G>A variant; − : negative for NC_000007.14(NM_015450.2):c.818G>A variant; (+) : obligate carrier of NC_000007.14(NM_015450.2):c.818G>A variant.

Comment in

References

    1. Henry ML Osborne JR, Else T. POT1 Tumor Predisposition. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews®. Seattle: University of Washington; 2020. - PubMed
    1. Wu Y, Poulos RC, Reddel RR. Role of POT1 in Human Cancer. Cancers. 2020;12:2739. 10.3390/cancers12102739 - DOI - PMC - PubMed
    1. Zade NH, Khattar E. POT1 mutations cause differential effects on telomere length leading to opposing disease phenotypes. J Cell Physiol. 2023;238:1237–55. 10.1002/jcp.31034 - DOI - PubMed
    1. Vassiliou G. Telomere Length and Clonal Hematopoiesis. N Engl J Med. 2023;388:2481–4. 10.1056/NEJMe2303022 - DOI - PubMed
    1. Gong Y, Stock AJ, Liu Y. The enigma of excessively long telomeres in cancer: lessons learned from rare human POT1 variants. Curr Opin Genet Dev. 2020;60:48–55. 10.1016/j.gde.2020.02.002 - DOI - PMC - PubMed

Publication types

LinkOut - more resources